Posts by: Magdalena Kegel

Magdalena Kegel

Magdalena is a writer with a passion for bridging the gap between the people performing research, and those who want or need to understand it. She writes about medical science and drug discovery. She holds an MS in Pharmaceutical Bioscience and a PhD — spanning the fields of psychiatry, immunology, and neuropharmacology — from Karolinska Institutet in Sweden.

June 7, 2017

Immune Design’s Immunotherapy Candidates Show Promise in Early Clinical Trials

News

Updated clinical trial data of Immune Design’s two lead immunotherapy candidates indicate the treatments hold promise to become new additions to the portfolio of immune-targeting compounds available to oncologists. Researchers ... Read more

April 24, 2017April 24, 2017

Immunotherapy Pioneer Jim Allison Makes TIME’s List of 100 Most Influential People

News

Dr. Jim Allison, an immuno-oncology pioneer at the University of Texas MD Anderson Cancer Center in Houston, has been named to TIME magazine’s list of the world’s 100 most influential people. Allison ... Read more

April 21, 2017

Opdivo for Head-Neck Cancers Too Costly for UK Patients, NICE Rules

News

Opdivo (nivolumab) likely will not be available for United Kingdom patients with head and neck cancers, because the U.K. cost-benefit agency, the National Institute for Health and Care Excellence (NICE), ... Read more

March 27, 2017March 27, 2017

Experimental Immunotherapy Offers Hope for Children with Brain Cancer

News

A new type of immunotherapy was highly effective against five types of childhood brain cancer when tested in mice. The treatment, which is already in clinical trials for other cancer ... Read more

March 17, 2017March 17, 2017

Computational Analysis of Immunotherapy Response Paints a Complex Picture

News

Using an advanced computational analysis may help scientists predict which patients are likely to respond to immunotherapy. But researchers — who hope a more integrated picture of the immune response might advance ... Read more

March 16, 2017

Identifying T-Cell Exhaustion Factors May Lead to New Immunotherapy Development

News

New insights into the molecular processes leading to the exhaustion of tumor-fighting T-cells may allow researchers to develop new methods of boosting cancer immunotherapy approaches. In a recent study titled “Exhaustion-associated ... Read more

March 7, 2017

Researchers Find Way to Pinpoint Best Cancer-fighting T-cells

News

A new technique will allow doctors to identify which T-cells in the soup of immune cells that are taken from a patient are most likely to combat a tumor. The ... Read more

January 23, 2017

Immune-cell Imaging May Shed Light on Why Cancer Treatments Fail

News

A new imaging technique can help doctors do a better job of monitoring the immune cells used in cancer immunotherapy by letting them track T-cell movements in the body, according ... Read more

January 16, 2017January 16, 2017

New Approach to Harnessing TGF-Beta Opens Door for Immunotherapy Development

News

Researchers have come up with a new solution to an old cancer problem, by developing antibodies that prevent TGF-beta signaling only on cancer cells. The discovery was made possible with ... Read more

December 12, 2016December 12, 2016

4 Tests That Determine Patient’s Suitability for PD-L1 Checkpoint Therapy Didn’t Agree in 37% of Cases, Study Finds

News

A comparison of four tests, used in clinical trials to determine if a patient will respond to treatment with checkpoint inhibitors targeting PD-L1, found considerable disagreement as to their results — suggesting that ... Read more